IL112520A0 - Treatment of normal tension glaucoma - Google Patents

Treatment of normal tension glaucoma

Info

Publication number
IL112520A0
IL112520A0 IL11252095A IL11252095A IL112520A0 IL 112520 A0 IL112520 A0 IL 112520A0 IL 11252095 A IL11252095 A IL 11252095A IL 11252095 A IL11252095 A IL 11252095A IL 112520 A0 IL112520 A0 IL 112520A0
Authority
IL
Israel
Prior art keywords
pct
treatment
normal tension
tension glaucoma
sec
Prior art date
Application number
IL11252095A
Other languages
English (en)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IL112520A0 publication Critical patent/IL112520A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL11252095A 1994-02-08 1995-02-02 Treatment of normal tension glaucoma IL112520A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08

Publications (1)

Publication Number Publication Date
IL112520A0 true IL112520A0 (en) 1995-05-26

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11252095A IL112520A0 (en) 1994-02-08 1995-02-02 Treatment of normal tension glaucoma

Country Status (17)

Country Link
US (1) US5889020A (es)
EP (1) EP0743852B1 (es)
JP (1) JPH09508641A (es)
CN (1) CN1140409A (es)
AT (1) ATE300287T1 (es)
AU (1) AU1423795A (es)
CA (1) CA2181461A1 (es)
CY (1) CY2567B1 (es)
DE (1) DE69534339T2 (es)
DK (1) DK0743852T3 (es)
ES (1) ES2243933T3 (es)
FI (1) FI963083A (es)
IL (1) IL112520A0 (es)
MX (1) MX9603259A (es)
NO (1) NO963064D0 (es)
WO (1) WO1995021609A1 (es)
ZA (1) ZA95958B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
WO1995024902A1 (fr) * 1994-03-16 1995-09-21 Sankyo Company, Limited Reducteur de tension oculaire
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
EP1870098A3 (en) * 1998-07-10 2010-07-07 Novartis Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
PT1197223E (pt) 1999-04-28 2005-04-29 Takeda Pharmaceutical Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa
CN1198650C (zh) * 1999-06-11 2005-04-27 三共株式会社 局部给药用眼压降低组合物
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EP1224945A4 (en) * 1999-10-25 2004-08-18 Senju Pharma Co MEANS TO RELEASE THE CELLARIAN TENSION
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
HUP0301057A3 (en) 2000-02-18 2004-01-28 Takeda Pharmaceutical Angiotenzin ii antagonist heterocyclic compound an their use for preparation of tnf-alpha inhibitors
WO2002045748A1 (fr) * 2000-12-05 2002-06-13 Sankyo Company, Limited Compositions d'abaissement de la tension oculaire pour administration topique
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CA2522318C (en) * 2003-04-15 2011-09-13 Sankyo Company Limited Drug for preventing or treating angiogenic eye diseases
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
PT1872783E (pt) * 2005-04-21 2012-01-16 Santen Pharmaceutical Co Ltd Agente terapêutico para distúrbio queratoconjuntivo
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
PT2376101E (pt) * 2008-12-29 2016-02-04 Trevena Inc Efectores da beta-arrestina e composições e métodos para a sua utilização
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
EP3102223A4 (en) 2014-02-07 2017-11-29 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9611293B2 (en) 2014-05-19 2017-04-04 Trevena, Inc. Synthesis of beta-arrestin effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03223281A (ja) * 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
ZA95958B (en) 1995-08-08
NO963064L (no) 1996-07-23
AU1423795A (en) 1995-08-29
MX9603259A (es) 1997-03-29
CA2181461A1 (en) 1995-08-17
NO963064D0 (no) 1996-07-23
CN1140409A (zh) 1997-01-15
CY2567B1 (en) 2008-07-02
DE69534339D1 (de) 2005-09-01
ATE300287T1 (de) 2005-08-15
DE69534339T2 (de) 2006-05-24
EP0743852A1 (en) 1996-11-27
JPH09508641A (ja) 1997-09-02
DK0743852T3 (da) 2005-10-17
WO1995021609A1 (en) 1995-08-17
ES2243933T3 (es) 2005-12-01
FI963083A (fi) 1996-08-07
FI963083A0 (fi) 1996-08-05
EP0743852B1 (en) 2005-07-27
US5889020A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
PL309347A1 (en) Application of anticonvulsive agents in therapy of neurological damages caused by or associated with injuries
IL142768A0 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
GB9317636D0 (en) Use of dexmedetomidine
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
TW324662B (en) Benzamide-containing pharmaceutical composition
CA2338066A1 (en) Treatment of dyskinesia
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
AU2001263130A1 (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
CA2311423A1 (en) Method for treating hyperlipidemia
PH31258A (en) New use of ropivacaine.
ZA965749B (en) Use of allylamines.
SE9404438D0 (sv) New process
DE69631597D1 (de) Kombination aus einem beta rezeptorblocker und einem opioid
CA2228572A1 (en) Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
NO306673B1 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse